Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 8231 results

  1. Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

    Awaiting development Reference number: GID-TA11671 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Apremilast for treating juvenile psoriatic arthritis in people 5 to 17 years [TSID12089]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]

    Awaiting development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Diclofenac–clotrimazole for Vulvovaginal candidiasis (VVC) [TSID 12053]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    In development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    In development